Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trilaciclib in ES-SCLC (TRACES)
NCT04902885Phase 3Completed
- Sponsor
- Simcere Pharmaceutical Group
- Start
- May 2021
- Primary completion
- Dec 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of trilaciclib in small cell lung cancer (SCLC), sponsored by Simcere Pharmaceutical Group. Started May 2021; status: completed.
02
Drugs
trilaciclib
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT04902885.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04902885.